$611 Million is the total value of Kynam Capital Management, LP's 30 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Buy | NATERA INC | $132,912,309 | -5.8% | 3,003,668 | +3.6% | 21.74% | +12.0% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $88,064,000 | -0.2% | 3,200,000 | +23.1% | 14.40% | +18.7% |
| PCVX | Buy | VAXCYTE INC | $66,396,709 | +2.3% | 1,302,407 | +0.2% | 10.86% | +21.6% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $52,272,000 | -23.4% | 3,600,000 | +10.4% | 8.55% | -8.9% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $40,527,487 | -15.8% | 2,956,053 | -1.5% | 6.63% | +0.1% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $30,335,199 | +12.6% | 1,818,657 | +86.5% | 4.96% | +33.9% |
| Buy | 2SEVENTY BIO INC | $23,338,994 | -52.8% | 5,953,825 | +21.7% | 3.82% | -43.9% | |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $22,609,472 | +58.3% | 3,932,082 | +0.2% | 3.70% | +88.2% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $22,183,006 | +10.6% | 3,133,193 | +10.0% | 3.63% | +31.5% |
| COGT | Buy | COGENT BIOSCIENCES INC | $21,548,719 | +12.5% | 2,210,125 | +36.6% | 3.52% | +33.8% |
| LQDA | Buy | LIQUIDIA CORPORATION | $12,680,000 | -1.6% | 2,000,000 | +21.8% | 2.07% | +17.0% |
| New | ACELYRIN INC | $12,204,000 | – | 1,200,000 | +100.0% | 2.00% | – | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $11,061,120 | -22.5% | 12,022,957 | +0.2% | 1.81% | -7.9% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $10,733,107 | -36.4% | 699,681 | -1.4% | 1.76% | -24.4% |
| TSHA | New | TAYSHA GENE THERAPIES INC | $10,368,949 | – | 3,281,313 | +100.0% | 1.70% | – |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $8,560,068 | -61.7% | 957,502 | -34.2% | 1.40% | -54.4% |
| BNR | BURNING ROCK BIOTECH LTDsponsored ads | $8,245,000 | -55.0% | 8,500,000 | 0.0% | 1.35% | -46.4% | |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $7,385,000 | – | 500,000 | +100.0% | 1.21% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INCcall | $5,808,000 | – | 400,000 | +100.0% | 0.95% | – |
| STRO | Buy | SUTRO BIOPHARMA INC | $5,387,782 | -22.8% | 1,552,675 | +3.5% | 0.88% | -8.1% |
| New | CARIBOU BIOSCIENCES INC | $5,107,559 | – | 1,068,527 | +100.0% | 0.84% | – | |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $4,726,154 | +4.7% | 730,472 | +0.2% | 0.77% | +24.5% |
| IMVT | New | IMMUNOVANT INCput | $3,839,000 | – | 100,000 | +100.0% | 0.63% | – |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $2,904,424 | -75.3% | 235,176 | -82.0% | 0.48% | -70.7% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $1,246,554 | -25.4% | 473,975 | +0.2% | 0.20% | -11.3% |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $434,003 | -28.0% | 535,005 | 0.0% | 0.07% | -14.5% | |
| GOSS | New | GOSSAMER BIO INC | $208,200 | – | 250,000 | +100.0% | 0.03% | – |
| TVTX | New | TRAVERE THERAPEUTICS INCcall | $134,994 | – | 15,100 | +100.0% | 0.02% | – |
| New | NEOLEUKIN THERAPEUTICS INC | $94,946 | – | 24,037 | +100.0% | 0.02% | – | |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $43,435 | +37.4% | 90,058 | +0.2% | 0.01% | +75.0% |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -119,966 | -100.0% | -0.01% | – |
| PTCT | Exit | PTC THERAPEUTICS INCcall | $0 | – | -28,500 | -100.0% | -0.16% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -92,602 | -100.0% | -0.21% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -586,500 | -100.0% | -0.22% | – |
| ARGX | Exit | ARGENX SEput | $0 | – | -184,300 | -100.0% | -9.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.